Platelet activation blocker affects clotting more than bleeding
Senior Science Editor
Blocking platelet aggregation by inhibiting the protease-activated receptor PAR4 prevented the formation of harmful blood clots, while having less of an effect on blood clots that repaired injury. The results, which were published in the Jan. 4, 2017, issue of Science Translational Medicine, "validate PAR4 as an antithrombotic target with the potential for a favorable safety/efficacy ratio," Michael Burgess, head of cardiovascular, fibrosis, immunoscience and GDD development at Bristol-Myers Squibb Co. (BMS), told BioWorld Today.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST